| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
WWL113 targets mouse carboxylesterase 3 (Ces3, also named Ces1d) and human CES1 (the orthologue of mouse Ces3). Ces3 mediates triglyceride hydrolysis in white adipose tissue, liberating free fatty acids into circulation. By inhibiting Ces3, WWL113 reduces lipolysis and fatty acid release. It shows excellent selectivity for Ces3 over several related enzymes.
|
|---|---|
| ln Vitro |
Endoplasmic reticulum glycoproteins Ces3 and Ces1f have been linked to adipocyte lipolysis in the past. At 10 μM, mouse recombinant Ces1, Ces1c, and ABHD6 are inhibited by WWL113 [1]. Brown adipocytes' UCP1 protein expression is markedly elevated by WWL113 (1 μM) [2]. PGE2 accumulation is somewhat and statistically significantly inhibited by WWL113 [3].
In vitro, WWL113 is a selective inhibitor of mouse Ces3 and human CES1 with IC₅₀ values of approximately 0.1 µM. It significantly reduces basal lipolysis in adipocytes. The compound was discovered by a high-throughput screen and shows excellent selectivity for the 60-kDa serine hydrolase family over several related enzymes. |
| ln Vivo |
WWL113 (30 mg/kg, orally once daily) can reduce non-esterified free fatty acids (NEFA), triglycerides (TG), total cholesterol, and fasting glucose levels while improving obesity-diabetes and improving several metabolic syndrome features in mice[1]. It can also improve glucose tolerance. Mice with diabetes and obesity can benefit from WWL113 [1].
In vivo, WWL113 corrects multiple features of metabolic syndrome in obese mice. As an orally active compound, it reduces basal lipolysis and improves metabolic parameters. Its ability to modulate lipid metabolism makes it a valuable tool for studying obesity, insulin resistance, and related metabolic disorders. |
| Enzyme Assay |
In vitro enzyme inhibition assays for WWL113 are performed using purified recombinant Ces3 or Ces1f enzymes. Enzyme activity is measured using fluorogenic or chromogenic ester substrates. The compound is incubated with the enzyme and substrate, and the inhibition of substrate hydrolysis is quantified. IC₅₀ values (~0.1 µM) are calculated from concentration-response curves.
|
| Cell Assay |
In vitro cellular assays for WWL113 are performed using adipocytes. Cells are treated with the compound, and basal lipolysis is measured by quantifying the release of free fatty acids or glycerol into the culture medium. The reduction in lipolysis is quantified, and the compound's efficacy is determined from concentration-response curves.
|
| Animal Protocol |
Animal/Disease Models: eightweeks old db/db mice (n = 10 per group) [1].
Doses: 30 mg/kg. How to take: Take orally one time/day for 3 weeks. Experimental Results: Multiple features of metabolic syndrome in db/db mice were corrected. In vivo animal experiments for WWL113 are conducted in mouse models of obesity and metabolic syndrome. A typical protocol involves oral administration of the compound to obese mice, followed by assessment of metabolic parameters including body weight, adipose tissue mass, circulating free fatty acids, glucose tolerance, and insulin sensitivity. |
| ADME/Pharmacokinetics |
WWL113 has a molecular weight of 466.53 and molecular formula C₂₉H₂₆N₂O₄. Its formal name is 4'-[[[methyl(3-(pyridin-4-yl)benzyl)carbamoyl]oxy]-[1,1'-biphenyl]-4-carboxylate. It is a crystalline solid soluble in DMF (25 mg/mL), DMSO (15 mg/mL), and ethanol (0.1 mg/mL). λmax is 269 nm. It should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for WWL113 are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human or veterinary use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
WWL113 is a member of the biphenyl class of compounds.
WWL113 is a selective Ces3/Ces1f inhibitor with IC₅₀ values of approximately 0.1 µM. It significantly reduces basal lipolysis in adipocytes and corrects multiple features of metabolic syndrome in obese mice. The compound is used in metabolic research to study lipid metabolism, obesity, and insulin resistance. This product is for research use only. |
| Molecular Formula |
C29H26N2O4
|
|---|---|
| Molecular Weight |
466.53
|
| Exact Mass |
466.189
|
| CAS # |
947669-86-5
|
| PubChem CID |
17759482
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
630.9±55.0 °C at 760 mmHg
|
| Flash Point |
335.4±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
5.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
35
|
| Complexity |
664
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)OC(=O)N(C)CC3=CC(=CC=C3)C4=CC=NC=C4
|
| InChi Key |
AKIIPHDGVCFVCC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H26N2O4/c1-3-34-28(32)25-9-7-22(8-10-25)23-11-13-27(14-12-23)35-29(33)31(2)20-21-5-4-6-26(19-21)24-15-17-30-18-16-24/h4-19H,3,20H2,1-2H3
|
| Chemical Name |
ethyl 4-[4-[methyl-[(3-pyridin-4-ylphenyl)methyl]carbamoyl]oxyphenyl]benzoate
|
| Synonyms |
WWL 113; WWL-113; WWL113
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~44.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1435 mL | 10.7174 mL | 21.4348 mL | |
| 5 mM | 0.4287 mL | 2.1435 mL | 4.2870 mL | |
| 10 mM | 0.2143 mL | 1.0717 mL | 2.1435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
